Who makes [225Ac]Ac-A9-3408?

[225Ac]Ac-A9-3408 is developed by Alpha-9 Oncology USA Inc..

What development phase is [225Ac]Ac-A9-3408 in?

[225Ac]Ac-A9-3408 is in Phase 1.

Last reviewed 2026-04-19 · How we verify

[225Ac]Ac-A9-3408

Alpha-9 Oncology USA Inc. · Phase 1 active Small molecule

At a glance

Generic name	[225Ac]Ac-A9-3408
Sponsor	Alpha-9 Oncology USA Inc.
Modality	Small molecule
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

[225Ac]Ac-A9-3408 CI brief — competitive landscape report
[225Ac]Ac-A9-3408 updates RSS · CI watch RSS
Alpha-9 Oncology USA Inc. portfolio CI